<?xml version="1.0"?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2014//EN" "http://www.ncbi.nlm.nih.gov/corehtml/query/DTD/pubmed_140101.dtd">
<PubmedArticle>
    <MedlineCitation Status="In-Process" Owner="NLM">
        <PMID Version="1">32088519</PMID>
        <DateRevised>
            <Year>2020</Year>
            <Month>11</Month>
            <Day>13</Day>
        </DateRevised>
        <Article PubModel="Print-Electronic">
            <Journal>
                <ISSN IssnType="Electronic">1872-6844</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>161</Volume>
                    <PubDate>
                        <Year>2020</Year>
                        <Month>03</Month>
                    </PubDate>
                </JournalIssue>
                <Title>Epilepsy research</Title>
                <ISOAbbreviation>Epilepsy Res</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Effects of enzyme-inducing antiseizure medication on vitamin D dosing in adult veterans with epilepsy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>106287</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="pii" ValidYN="Y">S0920-1211(19)30524-8</ELocationID>
            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.eplepsyres.2020.106287</ELocationID>
            <Abstract>
                <AbstractText Label="BACKGROUND">The association of antiseizure medication (ASM) and bone density abnormalities has long been recognized; however, there remains a lack of consensus on efficacy and optimal vitamin D dosing in patients receiving enzyme inducing and non-inducing ASMs. The objective was to explore the relationship between ASMs and vitamin D supplementation requirements in a population of adult patients with epilepsy.</AbstractText>
                <AbstractText Label="METHODS">Patients with a diagnosis of epilepsy receiving supplemental vitamin D were included in this retrospective chart review. All instances of 25-hydroxyvitamin D<sub>3</sub> (25-OHD) measured among those patients were compared between patients taking an enzyme inducing antiseizure medication (EIASM) to patients receiving ASM regimens only containing non-enzyme inducing antiseizure medications (NIASM). ASM use, prescription and over the counter (OTC) vitamin D use, 25-OHD plasma concentration, presence of chronic kidney disease (CKD), age, gender, and ethnicity were collected. Multiple linear regression was used to adjust for potentially confounding variables; the model included a cluster by participant term to account for repeated patients in the dataset.</AbstractText>
                <AbstractText Label="RESULTS">There were 542 vitamin D levels evaluated from 172 unique patients. There was an 11.5 % higher absolute percent increase in patients who achieved a 25-OHD level over 30 ng/mL in the NIASM (p = 0.012). Patients on EIASMs were supplemented with an additional 508 units of vitamin D daily (95 %CI 136-878, p = 0.007). When adjusted for CKD, OTC vitamin D use, OTC multivitamin use, age, gender, and ethnicity, patients on EIASMs were supplemented with an additional 445 units of vitamin D (95 %CI -69 to 960, p = 0.089) compared to NIASM use.</AbstractText>
                <AbstractText Label="CONCLUSIONS">Patients taking EIASMs had an increase in vitamin D deficiency and vitamin D supplementation suggesting that EIASMs impact vitamin D metabolism. Closer monitoring of vitamin D status in patients with epilepsy, especially those on EIASMs, is warranted. This evaluation suggests that for patients taking ASM, use of a lower dose OTC requires closer monitoring of vitamin D status in patients with epilepsy, especially those on EIASMs, is warranted. vitamin D agent may not be adequate.</AbstractText>
                <CopyrightInformation>Copyright Â© 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Menninga</LastName>
                    <ForeName>Nathan</ForeName>
                    <Initials>N</Initials>
                    <AffiliationInfo>
                        <Affiliation>William S. Middleton Memorial Veterans Hospital, Madison, WI, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Koukounas</LastName>
                    <ForeName>Yannis</ForeName>
                    <Initials>Y</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States; Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Margolis</LastName>
                    <ForeName>Amanda</ForeName>
                    <Initials>A</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States. Electronic address: Amanda.Margolis@wisc.edu.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Breslow</LastName>
                    <ForeName>Robert</ForeName>
                    <Initials>R</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Gidal</LastName>
                    <ForeName>Barry</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>University of Wisconsin-Madison School of Pharmacy, Madison, WI, United States.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
            </PublicationTypeList>
            <ArticleDate DateType="Electronic">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>05</Day>
            </ArticleDate>
        </Article>
        <MedlineJournalInfo>
            <Country>Netherlands</Country>
            <MedlineTA>Epilepsy Res</MedlineTA>
            <NlmUniqueID>8703089</NlmUniqueID>
            <ISSNLinking>0920-1211</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <KeywordList Owner="NOTNLM">
            <Keyword MajorTopicYN="Y">Antiseizure medication</Keyword>
            <Keyword MajorTopicYN="Y">Cholecalciferol</Keyword>
            <Keyword MajorTopicYN="Y">Drug interaction</Keyword>
            <Keyword MajorTopicYN="Y">Epilepsy</Keyword>
            <Keyword MajorTopicYN="Y">Ergocalciferol</Keyword>
            <Keyword MajorTopicYN="Y">Vitamin D</Keyword>
        </KeywordList>
        <CoiStatement>Declaration of Competing Interest Dr. Menninga has nothing to disclose. Dr. Koukounas has nothing to disclose. Dr. Margolis has received research support from UCB. Prof Breslow has nothing to disclose. Dr. Gidal has received honoraria from Eisai, Sunovion, Aquestive, and Greenwich.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="received">
                <Year>2019</Year>
                <Month>10</Month>
                <Day>31</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="revised">
                <Year>2020</Year>
                <Month>01</Month>
                <Day>28</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="accepted">
                <Year>2020</Year>
                <Month>02</Month>
                <Day>04</Day>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2020</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2020</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="entrez">
                <Year>2020</Year>
                <Month>2</Month>
                <Day>24</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">32088519</ArticleId>
            <ArticleId IdType="pii">S0920-1211(19)30524-8</ArticleId>
            <ArticleId IdType="doi">10.1016/j.eplepsyres.2020.106287</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>